Friday, May 23, 2008 - 18:30

Innate Pharma SA announces today the entry into regulatory pre-clinical development of IPH 2301, a novel monoclonal antibody targeting NK (Natural Killer) and T cells. It is the first antibody from the NK platform to be developed for the treatment of inflammatory conditions. 

AttachmentSize
PR in english40.52 KB
CP en français42.43 KB